“The global digital therapeutics market is expected to grow at a faster rate during the forecast period, owing to increase in smartphone penetration globally, especially in the developing countries. Moreover, rise in need to curb healthcare costs and increase in prevalence of chronic diseases are anticipated to supplement the market growth. In addition, the introduction of more sophisticated devices, which are compatible with smartphones and associated programs augments the growth of the market.”
The major companies involved in the global Digital Therapeutics Market include Proteus Digital Health, Inc., WellDoc, Inc., Livongo Health, Twine Health, Inc., Noom Inc., Omada Health Inc., 2Morrow, Inc., Propeller Health, Canary Health, Inc., and Medtronic Plc. These companies have adopted several strategies such as product launches, partnerships, mergers & acquisitions, joint ventures, collaborations, and others to gain a strong foothold in the industry.
The global digital therapeutics market was valued at $1,751 million in 2017 and is expected to reach $7,833 million by 2025 at a CAGR of 20.5% during the forecast period.
Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2117
Rapid penetration of smartphones & tablets and high prevalence of chronic diseases drive the growth of the global digital therapeutics market. In addition, increasing awareness about the benefits of digital therapeutics such as low healthcare expenditure, improved patient & doctor communication, and efficient management of patients’ health supplements the market growth. However, concerns regarding privacy of patients’ data hamper the growth of the industry. On the contrary, high growth potential in the emerging markets is expected to offer lucrative opportunities for the market players.
Obesity segment would manifest the fastest growth through 2025
Obesity segment is expected to grow at the fastest CAGR of 23.1% during the forecast period, as patients spend a copious amount of money to treat obesity. However, the diabetes segment would hold the largest market share, i.e., about 25% share of the total market by 2025. The report discusses applications such as cardiovascular diseases (CVD), central nervous system (CNS) disease, gastrointestinal disorders (GID), respiratory diseases, and smoking cessation, and others.
Software segment would remain dominant through 2025
In 2017, the software segment contributed about two-thirds of the market share and is expected to register the fastest CAGR of 20.6% during the study period. This is attributed to the increased utilization of software for transmitting patients’ data from wearable devices to physicians via different electronic devices. The report also includes an in-depth analysis of the devices segment.
Major sales channels in the market
The report includes an in-depth analysis of the major sales channels of the global digital therapeutics market including business-to-business (B2B) and business-to-consumer (B2C). In 2017, B2C segment garnered more than one-third share of the total market, owing to staggering sales of smartphone applications, online programs, and wearable devices. However, the B2B segment would grow at the fastest CAGR of 17.5% through 2025, as products are sold indirectly to customers through intermediaries such as Google Play and iOS app store, which in turn creates more profitable opportunities.
Asia-Pacific: the fastest-growing region
Asia-Pacific is expected to be the fastest-growing segment in the market by 2025, owing to rapid improvements in healthcare infrastructure and an increase in penetration of smartphones in developing countries such as India and China. However, North America would remain the dominant segment throughout the study period, contributing more than 41% of the total market share due to a large number of new product launches and favorable reimbursement scenario in the U.S. The other regions explored in the study include Europe and Latin America, Middle East and Africa (LAMEA).
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060